BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 15703504)

  • 1. Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors.
    Krobot KJ; Yin DD; Alemao E; Steinhagen-Thiessen E
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):37-45. PubMed ID: 15703504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization.
    Cooke CE; Hammerash WJ
    Clin Ther; 2006 Apr; 28(4):591-9. PubMed ID: 16750470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.
    Clearfield MB; Weis SE; Willis JM; Vasenius KA; McConathy WJ
    J Am Osteopath Assoc; 2002 Jul; 102(7):377-84. PubMed ID: 12138952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
    Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW;
    Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
    Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.
    Waters DD; Brotons C; Chiang CW; Ferrières J; Foody J; Jukema JW; Santos RD; Verdejo J; Messig M; McPherson R; Seung KB; Tarasenko L;
    Circulation; 2009 Jul; 120(1):28-34. PubMed ID: 19546386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
    Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of hypercholesterolemia in patients with diabetes at a family practice office.
    Camenga D; Gill JM
    Del Med J; 2003 Nov; 75(11):415-20. PubMed ID: 14870630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating cholesterol treatment rates among individuals with multiple risk factors and without coronary heart disease.
    Nag SS; Pearson TA; Ma L; Landsman PB; Cimino A; Vickers FF; Alexander CM; Melin JM
    Am J Cardiol; 2005 Apr; 95(7):862-4. PubMed ID: 15781017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS).
    Shlipak MG; Chaput LA; Vittinghoff E; Lin F; Bittner V; Knopp RH; Hulley SB;
    Am Heart J; 2003 Nov; 146(5):870-5. PubMed ID: 14597937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002.
    Keevil JG; Cullen MW; Gangnon R; McBride PE; Stein JH
    Circulation; 2007 Mar; 115(11):1363-70. PubMed ID: 17353444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
    Conard SE; Bays HE; Leiter LA; Bird SR; Rubino J; Lowe RS; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2008 Dec; 102(11):1489-94. PubMed ID: 19026302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary heart disease and dyslipidemia: a cross-sectional evaluation of prevalence, current treatment, and clinical control in a large cohort of Spanish high-risk patients: the PRINCEPS study.
    de Rojas FD; De Frutos T; Ponte A; Chacón JM; Vitale GC;
    Prev Cardiol; 2009; 12(2):65-71. PubMed ID: 19476579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates.
    Baessler A; Fischer M; Huf V; Mell S; Hengstenberg C; Mayer B; Holmer S; Riegger G; Schunkert H
    Int J Cardiol; 2005 May; 101(2):293-8. PubMed ID: 15882678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.